Neoadjuvant Chemotherapy in Breast Cancer

  • Neoadjuvant chemotherapy:
    • Does not prolong survival compared to adjuvant chemotherapy:
      • However, it does result in decreased disease burden, and can be beneficial at time of surgery:
        • Providing increased opportunity to perform breast-conserving surgery and reducing need for axillary lymph node dissection
  • A meta-analysis of 14 prospective randomized trials of neoadjuvant vs. adjuvant chemotherapy:
    • In 5,500 patients with breast cancer demonstrated that:
      • NAC was associated with an absolute decrease in the mastectomy rate of 16.6% (95% CI 15.1–18.1%)
      • Patients with ER– and HER2 positive breast cancers:
        • Are more likely to experience complete pathologic response than those with ER+ cancers
  • Patients with a clinically positive axilla after neoadjuvant chemotherapy:
    • Should undergo axillary dissection at the time of breast surgery
  • Patients with no residual adenopathy on clinical exam:
    • May be considered for sentinel lymph node biopsy (SLNB):
      • Accuracy of SLNB after NAC can be improved with:
        • Localization of previously-clipped nodes
        • Use of dual tracer
        • Increasing the number of sentinel nodes retrieved:
          • SLNB after NAC has a false-negative rate of less than 10% only when ≥ 3 sentinel nodes were identified
  • References
    • Mieog, JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94(1):1189-1200.
    • van der Hage JA, van de Velde CJH, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19(22):4224-4237.
    • Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483-2493.
    • Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678-5685.
    • Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802-807.
    • Boileau, JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258-264.

#Arrangoiz #BreastCancer #BreastSurgeon #CancerSurgeon #SurgicalOncologist #CASO #CenterforAdvancedSurgicalOncology

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s